Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus and Pegylated Liposomal Doxorubicin in Advanced HCC
NCT01281943Phase 2Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Jun 2011
- Primary completion
- Jul 2012
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of temsirolimus in hepatocellular carcinoma (HCC), sponsored by Washington University School of Medicine. Primary endpoint: Progression Free Survival at 15 months. Planned start Jun 2011; status: withdrawn.
02
Drugs
temsirolimus
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01281943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01281943.